V1RJ2 Inhibitors
V1RJ2 inhibitors pertain to a class of chemical compounds designed to selectively interact with a specific biological target known as V1RJ2, which is a protein or receptor encoded by a corresponding gene. The detailed mechanism of action for such inhibitors involves the precise binding to this receptor, resulting in the modulation of its activity. In the complex web of biochemical interactions within living organisms, the function of proteins such as V1RJ2 is often a critical component in various physiological processes. The inhibitors are structured to fit into the receptor's active site or another relevant binding site, blocking or altering the normal interaction that the receptor would typically engage in within the biological system. This blockade or modification can lead to changes in the downstream signaling pathways that are normally initiated by the activation of the receptor.
The development of V1RJ2 inhibitors is a sophisticated process that requires a deep understanding of molecular biology, chemistry, and the structural biology of the target receptor. Researchers utilize various techniques such as X-ray crystallography, computational modeling, and medicinal chemistry to design molecules that exhibit high specificity and affinity for the V1RJ2 receptor. The selectivity of these compounds is crucial, as it ensures minimal off-target effects, which is a common challenge in the design of such inhibitors. The chemical characteristics of V1RJ2 inhibitors, such as solubility, stability, and reactivity, are fine-tuned to optimize their interaction with the receptor. Moreover, the pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are also taken into consideration during the design phase to ensure that these compounds can reach their intended site of action in the biological system without being prematurely degraded or eliminated.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palmitoleic acid | 373-49-9 | sc-205424 sc-205424A sc-205424B sc-205424C sc-205424D | 100 mg 500 mg 1 g 5 g 10 g | $33.00 $135.00 $238.00 $1039.00 $1907.00 | 4 | |
Palmitoleic acid is a monounsaturated fatty acid that can incorporate into cell membrane phospholipids, altering membrane fluidity and receptor-associated signaling. V1RJ2, a receptor protein, could have its functional activity inhibited by such alteration in membrane properties, leading to decreased signal transduction efficiency. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a Raf kinase inhibitor that impedes the MAPK/ERK signaling cascade, which could be upstream of V1RJ2. By inhibiting this pathway, the phosphorylation and activation of proteins that might regulate V1RJ2 activity can be diminished. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3 kinase inhibitor. By interfering with the PI3K/Akt pathway, it can dampen the signaling that may converge on the regulation of V1RJ2, thereby reducing its activation and signaling output. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream in the MAPK/ERK pathway. Inhibition of MEK can lead to reduced activation of downstream effectors that may control the activation state or expression of V1RJ2. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W7 hydrochloride is a calmodulin antagonist that impedes calcium-calmodulin-dependent protein kinase (CaMK) signaling. If V1RJ2 is regulated by CaMK, this inhibitor could reduce V1RJ2 activity by preventing its phosphorylation or altering its conformation. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. It can inhibit the phosphorylation of proteins that are upstream regulators or direct interactors of V1RJ2, thus potentially reducing the functional activity of V1RJ2 through decreased phosphorylation signaling. | ||||||
NF 449 | 389142-38-5 | sc-203159 | 10 mg | $314.00 | 5 | |
NF449 is a potent Gs alpha subunit-selective antagonist, which can inhibit G-protein coupled receptor signaling. If V1RJ2 is a GPCR or is regulated by GPCR signaling, NF449 could lead to a decrease in V1RJ2-mediated signal transduction. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
AG 1478 is an EGFR tyrosine kinase inhibitor. If V1RJ2 signaling is modulated through EGFR-mediated pathways, this inhibitor could decrease V1RJ2 activity by reducing EGFR signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. It could indirectly inhibit V1RJ2 by reducing protein synthesis and cellular processes that are crucial for V1RJ2 function, as mTOR signaling is involved in the regulation of protein translation and cell growth. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine chloride is a potent inhibitor of protein kinase C (PKC). If V1RJ2 signaling is regulated by PKC-mediated phosphorylation, this compound would decrease V1RJ2 activity by inhibiting PKC. | ||||||